Standard of care treatment

Phase 3

Johnson & Johnson

Standard of care treatment is one of 52 therapeutic programs targeting Myasthenia Gravis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Myasthenia GravisRecruiting

Sjogren's SyndromeActive, not recruiting

Myasthenia GravisPreclinical

Recruiting

Sjogren's SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

102 competitors in Myasthenia Gravis

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

7 2

Ultomiris

AstraZeneca

Phase 3

5 3

Vyvgart

Argenx

Phase 3

17 4

Zilbrysq

UCB

Phase 3

4 5

Soliris

AstraZeneca

Phase 3

4 6

Cellcept

Roche

Phase 3

4 7

Fabhalta

Johnson & Johnson

Phase 3

3 8

Rhapsido

Novartis

Phase 3

1 9

Arava

Sanofi

Phase 3

1 10

ENSPRYNG

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Myasthenia Gravis

NCT06193889

Q2 2029

Phase 3Active, not recruiting

Sjogren's Syndrome

NCT06741969

Clinical

Trials by Indication[1]

Myasthenia Gravis1 trial

KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients With Generalized Myasthenia Gravis

Recruiting·KKyverna Therapeutics·Preclinical·NCT06193889·66 enrolled

Sjogren's Syndrome1 trial

A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults With Moderate to Severe Sjogren's Disease (SjD)

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06741969·655 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Standard of care treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Standard of care treatment. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Standard of care treatment

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q2 2029

Trials by Indication[1]

Myasthenia Gravis1 trial

Sjogren's Syndrome1 trial

References

Drug Info

Quick Facts

Related News